Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1996-12-10
|
pubmed:abstractText |
There is some evidence that Parkinson's disease (PD) seems to be a heterogenous and generalized brain disorder reflecting a degeneration of multiple neuronal networks, including somatostatinergic neurons. Somatostatin-like immunoreactivity (SLI) and its molecular forms, high molecular weight form (HMV-SST), somatostatin-14 (SST-14), somatostatin-25/28 (SST-25/28) and Des-ala-somatostatin (Des-ala-SST), as well as homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were estimated using HPLC and radioimmunoassay in the cerebrospinal fluid (CSF) of 35 aged parkinsonian patients with different stages of intellectual deterioration. The influence of L-dopa-treatment on these neurochemical parameters was evaluated. Without a correlation with dementia scores (p = 0.11), SLI was significantly reduced in PD in comparison to the control group (p < 0.05). The reduction was related to the progression of the disease. Correlations between SLI, HVA and 5-HIAA indicate a heterogenous brain disorder in PD with alterations of several transmitter systems and functions. Complex qualitative and quantitative changes in the molecular pattern of SLI are compatible with a dysregulated synthesis and/or posttranslational processing. L-dopa-treatment was associated with a significant increase of HVA (p < 0.05) and HMV-SST (p < 0.05) and a slight, but insignificant increase of SLI (p = 0.11).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biogenic Monoamines,
http://linkedlifedata.com/resource/pubmed/chemical/Homovanillic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyindoleacetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Somatostatin,
http://linkedlifedata.com/resource/pubmed/chemical/somatostatin-like peptides
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0300-9564
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
103
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
591-602
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8811504-Aged,
pubmed-meshheading:8811504-Aged, 80 and over,
pubmed-meshheading:8811504-Aging,
pubmed-meshheading:8811504-Biogenic Monoamines,
pubmed-meshheading:8811504-Dementia,
pubmed-meshheading:8811504-Female,
pubmed-meshheading:8811504-Homovanillic Acid,
pubmed-meshheading:8811504-Humans,
pubmed-meshheading:8811504-Hydroxyindoleacetic Acid,
pubmed-meshheading:8811504-Male,
pubmed-meshheading:8811504-Molecular Weight,
pubmed-meshheading:8811504-Parkinson Disease,
pubmed-meshheading:8811504-Peptides,
pubmed-meshheading:8811504-Somatostatin
|
pubmed:year |
1996
|
pubmed:articleTitle |
Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.
|
pubmed:affiliation |
Department of Neurology, University of the Saarland, Homburg, Federal Republic of Germany.
|
pubmed:publicationType |
Journal Article
|